anti-Nipah_074
| anti-Nipah_ID | anti-Nipah_074 |
| anti-Nipah Drug | Gliotoxin |
| Nipah virus strain | NiV (Malaysia-1999) |
| Approaches used to test anti-Nipah activity | Experimental |
| Methods used to test anti-Nipah activity | in-vitro |
| Models used to test anti-Nipah activity | Vero |
| Mode of infection to test anti-Nipah activity | Adsorption |
| Viral titer to test anti-Nipah activity | 1000 TCID50 |
| Mode of Drug delivery for anti-Nipah activity | Culture |
| Time of Drug delivery for anti-Nipah activity | During infection |
| Duration of Drug delivery for anti-Nipah activity | Overnight |
| Drug concentration used to test anti-Nipah activity | 0.1 μM |
| Assays used to test anti-Nipah activity | TCID50 |
| anti-Nipah activity | Decrease [Viral titer (>100 TCID50/ml)] |
| References | Aljofan M, Sganga ML, Lo MK, Rootes CL, Porotto M, Meyer AG, Saubern S, Moscona A, Mungall BA. Antiviral activity of gliotoxin, gentian violet and brilliant green against Nipah and Hendra virus in vitro. Virol J. 2009 Nov 4;6:187. doi: 10.1186/1743-422X-6-187 |
| Comments | Gliotoxin, gentian violet and brilliant green have been used previously for various aspects of anti-bacterial and anti-fungal therapy and the current results suggest that while unsuitable for internal administration, they may be amenable to topical antiviral applications, or as disinfectants and provide excellent positive controls for future studies. |